Events – TransBioline

Skip to content

Home
Project
Consortium
News
Recruitment
- Clinical Studies
Login
Search for:

Loading...

Events

Events2023-07-18T23:01:18+00:00

Upcoming Activities and Events

7th Consortium Meeting, Basel
October 2023

IMI2_TransBioLine @imitransbioline ·

25 Sep

Real-world retrospective cohort study shows that @ChILI is higher than reported
Find out more here
👉
#safetybiomarkers #IHICarryTheTorch #H2020 #EUHealthResearch @IHIEurope

Reply on Twitter 1706186770499436658 Retweet on Twitter 1706186770499436658 1 Like on Twitter 1706186770499436658 Twitter 1706186770499436658

Load More

ABOUT IMI

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world's biggest public-private partnership (PPP) in the life sciences.

Subscribe to our Newsletter

Leave this field empty if you're human:

ACKNOWLEDGEMENT

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies.

info@transbioline.com

© Copyright | TransBioLine | Disclaimer: The TransBioLine website reflects the author’s view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.

This website uses cookies and third party services. Ok